Scaled up base portfolio: The company has a base portfolio in long standingGastrointestinal and Antimigraine accounting for close to 40% of existing portfolio.Operating in such long standing therapies, the company delivered Rs. 5000 Mn inrevenues in FY14 (111% YoY) and sustained the scale with 12% growth in FY15.